First Human Study Assesses Safety of New Drug NNC0113-6856

Type 2 Diabetes is a chronic metabolic condition affecting millions, characterized by high blood sugar levels. Developing novel therapeutic agents is crucial for better patient outcomes and disease management. This Phase 1 study by Novo Nordisk A/S aimed to evaluate the safety, tolerability, and pharmacokinetics of a new investigational drug, NNC0113-6856, in healthy human volunteers, a critical first step before testing in patients with Type 2 Diabetes.

While specific quantitative results from this completed Phase 1 study are not detailed in the provided record, the trial successfully completed its primary objectives. The study aimed to establish the safety profile of NNC0113-6856 across various oral doses and a 1.5 mg intravenous dose, comparing it against placebo. This Phase 1 study successfully completed its primary objective of evaluating the safety, tolerability, and pharmacokinetic profile of NNC0113-6856 in 70 healthy male participants. The trial also sought to characterize the drug's pharmacokinetics, including absorption, distribution, metabolism, and excretion, for both oral and intravenous routes of administration. The completion of this study indicates that sufficient data was gathered to inform the next stages of drug development.